Diabetic Neuropathy – Epidemiology – Asia Pacific
DRG Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of diabetic neuropathy for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered.
DRG Epidemiology’s diabetic neuropathy forecast will answer the following questions:
- How many people, in each of the major mature pharmaceutical markets have diabetic neuropathy?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of diabetic neuropathy over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Note: Coverage may vary by country.
Table of contents
- Diabetic Neuropathy - Epidemiology - Asia Pacific
- Introduction
- Key Findings
- Prevalence of Diabetic Neuropathy per 1,000 Among People Aged 20+ in 2018 and 2028ttttttttttttttttttttttttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Diabetic Neuropathy over the Next Ten Yearsttttttttttttttttt
- Key Findings
- Epidemiology Data
- Methods
- Total Prevalent Cases of Diabetic Neuropathy
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Diabetic Neuropathy
- Studies Excluded from the Analysis of Diabetic Neuropathy
- Risk/Protective Factors
- Risk/Protective Factors for Diabetic Neuropathy
- Bibliography
- Literature Review
- Introduction
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.